FDA Approves Nipocalimab to Treat Sjögren’s Disease

Johnson & Johnson’s (J&J) anti-FcRn antibody nipocalimab is the first investigational therapy to be granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) as a treatment for adults with moderate-to-severe Sjögren’s disease (SjD). Nipocalimab is designed to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies, potentially without impact on other immune functions.

Approval was based on positive results from the mid-stage DAHLIAS study evaluating its effects in more than 160 adults with moderately-to-severely active primary SjD who were seropositive for anti-Ro60 and/or anti-Ro52 IgG antibodies. Results demonstrated a statistically significant and clinically meaningful improvement in ClinESSDAI score, which measures disease activity across 11 organ systems, in nipocalimab-treated SjD patients versus placebo at 24 weeks compared to baseline.

According to Terence Rooney, vice president of rheumatology and immunology disease area leader at J&J Innovative Medicine, this “marks an important step forward in the continued research and development of nipocalimab, the first investigational FcRn blocker to demonstrate positive results in a Phase II study in adult patients with moderate-to-severe SjD. With no treatments currently approved that may directly address the underlying cause(s) of the disease, innovation is critically needed to improve patient outcomes in SjD.”

A Phase III trial of the candidate in SjD is currently underway.

References

  1. Kimber, E. J&J’s Nipocalimab Granted FDA Breakthrough Designation for Sjögren’s Disease. PMLive, Nov. 13, 2024. Accessed at pmlive.com/pharma_news/jjs-nipocalimab-granted-fda-breakthrough-designation-for-sjogrens-disease.
BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.